NuCana Stock to Reverse Split on Friday, August 8th (NASDAQ:NCNA)

NuCana PLC Sponsored ADR (NASDAQ:NCNA)’s stock is going to reverse split before the market opens on Friday, August 8th. The 1-200 reverse split was announced on Friday, July 11th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, August 7th.

NuCana Price Performance

Shares of NASDAQ NCNA opened at $0.05 on Thursday. The company has a 50 day simple moving average of $0.07 and a 200 day simple moving average of $0.54. The firm has a market cap of $283,936.00, a PE ratio of -0.01 and a beta of 1.42. NuCana has a 1 year low of $0.03 and a 1 year high of $10.79.

NuCana (NASDAQ:NCNA) last released its quarterly earnings results on Monday, June 2nd. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.62). As a group, research analysts anticipate that NuCana will post -13.42 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in NCNA. Two Sigma Securities LLC bought a new position in NuCana during the 4th quarter worth approximately $25,000. Citadel Advisors LLC bought a new position in NuCana during the 4th quarter worth approximately $30,000. Virtu Financial LLC bought a new position in NuCana during the 4th quarter worth approximately $48,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in NuCana during the 4th quarter worth approximately $54,000. Institutional investors own 44.00% of the company’s stock.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.